Infliximab Maintains IBD Remission Longer with Dose Adjustment and Monitoring

Infliximab Maintains IBD Remission Longer with Dose Adjustment and Monitoring

It is estimated that roughly 1.4 million Americans suffer from inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis. Every year, over 30,000 new IBD diagnoses are made, and yet science has yet to determine this debilitating condition's cause, nor has it found a reliable cure.

One of the drugs indicated for IBD, infliximab, was recently the subject of a study now published in the Inflammatory Bowel Diseases journal. In this observational study, conducted at the Beth Israel Deaconess Medical Center, the researchers recommended proactive monitoring and appropriate dose adjustment of the drug in order to enhance and prolong patients' long-term therapeutic response.
Infliximab is an anti-tumor necrosis factor antibody. Specifically, it inhibits TNF-alpha -- a protein found in abnormally high amounts in IBD patients and those with other inflammatory diseases. More popularly referred to with its brand name, Remicade, this drug is 1 of only 4 approved anti-T
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *